Scholarlink

<p>Chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment of haematological malignancies and continues to transform the treatment of various other diseases. Nonetheless, current CAR-T cell therapy has limitations that hinder its therapeutic efficacy for expanded applications, some of which might be attributed to intrinsic T cell features. Using immune cells beyond conventional T cells has therefore emerged as a promising strategy to compensate for such limitations. In this Review, we discuss different CAR-engineered immune cells for therapeutic applications by highlighting how unique immune attributes, along with cell-specific manufacturing strategies and CAR designs, address challenges faced by conventional CAR-T cell therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

CAR-X cell engineering

  • 期刊论文

  • 发表日期：

    2026年4月27日

查看全文
  • Xia Li,
  • Haikun Lin,
  • Jiehan Liang,
  • Xin Jin,
  • Tingfeng Shen,
  • Yongxian Hu,
  • He Huang

摘要

Chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment of haematological malignancies and continues to transform the treatment of various other diseases. Nonetheless, current CAR-T cell therapy has limitations that hinder its therapeutic efficacy for expanded applications, some of which might be attributed to intrinsic T cell features. Using immune cells beyond conventional T cells has therefore emerged as a promising strategy to compensate for such limitations. In this Review, we discuss different CAR-engineered immune cells for therapeutic applications by highlighting how unique immune attributes, along with cell-specific manufacturing strategies and CAR designs, address challenges faced by conventional CAR-T cell therapy.